Shots: Medical Developments International (MVP) to receive up to $32.5M (AUD $45.8M) as total deal value plus $15M upfront and additional sales-based milestones payments MVP will fund the regulatory process […]readmore
Tags : Exclusive
Shots: The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional […]readmore
Shots: Celyad to get hold of Horizon’s shRNA technology for generation and development of allogenic CAR-T therapies shRNA (Short hairpin) technology is based on DNA and contains a selectable marker […]readmore
Shots: Teva launches generic version of Cialis (tadalafil) tablets with dosage (2.5 mg, 5 mg, 10 mg, 20 mg) in the US, with 180 days ANDA exclusivity before the FDA […]readmore
Shots: Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct […]readmore
Shots: Verastem will receive an upfront of $15M with up to $30M for development milestones, additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib) CSPC to get […]readmore
Shots: The agreement will focus on commercialization of kidney organoid technology, for generation of human pluripotent stem cell-derived kidney organoids This technology enables the growth of organoids/ mini-organs, having key […]readmore
Shots: Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer Accordingly, Novartis will acquire equity stake in Laenka adding […]readmore
Shots: With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety To identify specific subgroups population to develop targeted treatments GSK is initially […]readmore